Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PDX-Rx Works To Collaborate With Microsoft
PDX and Rx.com have entered into a strategic agreement with Microsoft to make prescription data, which Rx.com manages for multiple chain and independent pharmacy clients, available to Microsoft
PDX and Rx.com have entered into a strategic agreement with Microsoft to make prescription data, which Rx.com manages for multiple chain and independent pharmacy clients, available to Microsoft
iMedica Corporation, a leading developer of healthcare software solutions for physician practices, announced that after more than two years of research and consideration, the Physicians’ Organization of the
The VerifyNow System assesses response to antiplatelet therapies, such as aspirin, Plavix and GP IIb/IIIa inhibitors. As response to these drugs varies, the tests help physicians ensure their
Millipore expects the new facility will employ 120 before the end of 2009. The company currently employs over 1,000 in Massachusetts and almost 6,000 around the world. Millipore’s
Highlights of the Quarter: The second quarter of 2009 marked a turning point for DiagnoCure’s two commercialized tests, PCA3 for prostate cancer and Previstage GCC for colorectal cancer.
Progenics and Ono Pharmaceutical announced that they have started clinical testing of RELISTOR (methylnaltrexone bromide) subcutaneous injection in Japan. Its the first in class medicine approved in the
Sangamo has announced positive Phase-II clinical data from its ZFP Therapeutic program, to develop SB-509 as a treatment for diabetic neuropathy (DN). Data from SB-509-601 and SB-509-701A Phase
AEterna Zentaris, after regaining from Ardana the worldwide rights to the growth hormone secretagogue (GHS)/ghrelin agonist, AEZS-130, has signed an agreement with Ardana to acquire all its assets
Sanofi-Aventis has announced that Sanofi-Aventis Deutschland has purchased the Diabel manufacturing plant in Frankfurt-Hochst, Germany, from Pfizer. Sanofi-Aventis is exercising its step in the right direction, regarding a
ISTA has declared positive results for Phase-II clinical study in subjects with dry eye disease (keratoconjuctivitis sicca). The company used its proprietary, low-dose formulation of bromfenac, the active